Annabelle Stoclin
Annabelle Stoclin has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Arthur Geraud
Institut Gustave Roussy 1 Drug Development Department Villejuif, France
2 shared publications - Aurelien Marabelle
University of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France
2 shared publications - Fabrice André
Gustave Roussy, Villejuif, France
2 shared publications - Fabrice Barlesi
Department of Medical Oncology, Gustave Roussy, Villejuif, France
2 shared publications - François-Xavier Danlos
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2 shared publications - Jean-Charles Soria
Département de Médecine, SITEP; and
2 shared publications
Latest Publications
- Top Cited Papers
- 4 May 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 205, 114075
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
- 4 May 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 205, 114075
Top Cited PapersReactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
- Open Access
- 27 November 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 139, 13-20
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry
- 27 November 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 139, 13-20
Open AccessPrevious immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry
- 30 May 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (22) , E2247-E2258
Outcomes in Patients With COVID-19 With Acute Encephalopathy and Coma
Objective: To report the prevalence of acute encephalopathy and outcomes in patients with severe COVID-19, and to identify determinants of 90-day outcomes. Methods: Data from adults with severe COVID-19 and acute encephalopathy were prospectively collected for patients requiring intensive care unit management in 31 university or university-affiliated in six countries (France, USA, Colombia, Spain, Mexico, Brazil) between March and September of 2020. Acute encephalopathy was defined, as recently recommended, as subsyndromal delirium or delirium, or as a comatose state in case of severely decreased level of consciousness. Logistic multivariable regression was performed to identify factors associated with 90-day outcomes. A Glasgow Outcome Scale−Extended score (GOS-E) of 1−4 was considered a poor outcome (indicating death, vegetative state, or severe disability). Results: Of 4060 patients admitted with COVID-19, 374 (9.2%) experienced acute encephalopathy at or prior to the ICU admission. A total of 199/345 (57.7%) patients had a poor outcome at 90-day follow-up as evaluated by the GOS-E (29 patients were lost to follow-up). On multivariable analysis, age >70 years (odds ratio [OR] 4.01, 95% confidence interval [CI], 2.25−7.15), presumed fatal comorbidity (3.98, 1.68−9.44), Glasgow Coma Scale score <9 before/at ICU admission ICU admission (2.20, 1.22−3.98), vasopressor/inotrope support during ICU stay (3.91, 1.97−7.76), renal replacement therapy during ICU stay (2.31, 1.21−4.50), and CNS ischemic or hemorrhagic complications as acute encephalopathy etiology (3.22, 1.41−7.82) were independently associated with higher odds of poor 90-day outcome. Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome were associated with lower odds of poor 90-day outcome (OR 0.15, 95% CI 0.03−0.83). Conclusions and Relevance: In this observational study, we found a low prevalence of acute encephalopathy at ICU admission in COVID-19 patients. Over a half of patients with COVID-19 presenting with acute encephalopathy had poor outcomes as evaluated by GOS-E. Determinants of poor 90-day outcome were dominated by older age, comorbidities, degree of impairment of consciousness before/at ICU admission, association with other organ failures, and acute encephalopathy etiology. Trial Registration: The study is registered with ClinicalTrials.gov, number NCT04320472
- 30 May 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (22) , E2247-E2258
Outcomes in Patients With COVID-19 With Acute Encephalopathy and Coma
Objective: To report the prevalence of acute encephalopathy and outcomes in patients with severe COVID-19, and to identify determinants of 90-day outcomes. Methods: Data from adults with severe COVID-19 and acute encephalopathy were prospectively collected for patients requiring intensive care unit management in 31 university or university-affiliated in six countries (France, USA, Colombia, Spain, Mexico, Brazil) between March and September of 2020. Acute encephalopathy was defined, as recently recommended, as subsyndromal delirium or delirium, or as a comatose state in case of severely decreased level of consciousness. Logistic multivariable regression was performed to identify factors associated with 90-day outcomes. A Glasgow Outcome Scale−Extended score (GOS-E) of 1−4 was considered a poor outcome (indicating death, vegetative state, or severe disability). Results: Of 4060 patients admitted with COVID-19, 374 (9.2%) experienced acute encephalopathy at or prior to the ICU admission. A total of 199/345 (57.7%) patients had a poor outcome at 90-day follow-up as evaluated by the GOS-E (29 patients were lost to follow-up). On multivariable analysis, age >70 years (odds ratio [OR] 4.01, 95% confidence interval [CI], 2.25−7.15), presumed fatal comorbidity (3.98, 1.68−9.44), Glasgow Coma Scale score <9 before/at ICU admission ICU admission (2.20, 1.22−3.98), vasopressor/inotrope support during ICU stay (3.91, 1.97−7.76), renal replacement therapy during ICU stay (2.31, 1.21−4.50), and CNS ischemic or hemorrhagic complications as acute encephalopathy etiology (3.22, 1.41−7.82) were independently associated with higher odds of poor 90-day outcome. Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome were associated with lower odds of poor 90-day outcome (OR 0.15, 95% CI 0.03−0.83). Conclusions and Relevance: In this observational study, we found a low prevalence of acute encephalopathy at ICU admission in COVID-19 patients. Over a half of patients with COVID-19 presenting with acute encephalopathy had poor outcomes as evaluated by GOS-E. Determinants of poor 90-day outcome were dominated by older age, comorbidities, degree of impairment of consciousness before/at ICU admission, association with other organ failures, and acute encephalopathy etiology. Trial Registration: The study is registered with ClinicalTrials.gov, number NCT04320472
- Open Access
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19 + ), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Chronic viral RNA carriers exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of non-conventional monocytes and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T helper cells, and non-naive Granzyme B + FasL + , Eome high TCF-1 high , PD-1 + CD8 + Tc1 cells. Virus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA shedding, COVID-19 severity and a higher risk of cancer-related death in the first and second surge of the pandemic. Lymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood DNA from Enterobacteriaceae and Micrococcaceae gut family members in long term viral carriers. We surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and COVID-19-related immunopathology, and that the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated death.
Open AccessProlonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19 + ), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Chronic viral RNA carriers exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of non-conventional monocytes and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T helper cells, and non-naive Granzyme B + FasL + , Eome high TCF-1 high , PD-1 + CD8 + Tc1 cells. Virus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA shedding, COVID-19 severity and a higher risk of cancer-related death in the first and second surge of the pandemic. Lymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood DNA from Enterobacteriaceae and Micrococcaceae gut family members in long term viral carriers. We surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and COVID-19-related immunopathology, and that the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated death.
- 30 July 2020
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 48 (10) , 1471-1479
Association Between Anxiety and New Organ Failure, Independently of Critical Illness Severity and Respiratory Status: A Prospective Multicentric Cohort Study
Objectives: Anxiety results from the anticipation of a threat and might be associated with poor outcome in the critically ill. This study aims at showing that anxiety at admission in critically ill patients is associated with new organ failure over the first 7 days of ICU hospitalization independently of baseline organ failure at admission. Design: Prospective multicenter cohort study. Setting: Three mixed ICU from April 2014 to December 2017. Patients: Coma-, delirium-, and invasive mechanical ventilation-free patients admitted to the ICU were included. Interventions: None. Measurements and Main Results: “State anxiety” was assessed using the state component of the State-Trait Anxiety Inventory State. Severity of illness was measured using Simplified Acute Physiology Score II and Sequential Organ Failure Assessment scores. Primary endpoint was a composite of occurrence of death or new organ failure in the first 7 days after admission. Three hundred ninety-one patients were included; 159 of 391 women (40.7%); median age 63 years (49–74 yr); median Simplified Acute Physiology Score II 28 (19–37). Two hundred three out of 391 patients (51.9%) reported moderate to severe anxiety (State-Trait Anxiety Inventory State ≥ 40). One hundred two out of 391 patients (26.1%) developed a new organ failure. After adjustment to Simplified Acute Physiology Score II and Sequential Organ Failure Assessment, State-Trait Anxiety Inventory State greater than or equal to 40 was associated with the primary endpoint (odds ratio, 1.94; 95% CI, 1.18–3.18; p = 0.009) and respiratory failure. In post hoc analysis, State-Trait Anxiety Inventory State greater than or equal to 40 was associated with new organ failure independently and notably of respiratory status at admission (dyspnea-Visual Analogic Scale and Paco 2 ≥ 45 mm Hg). Conclusions: Moderate to severe anxiety at ICU admission is associated with early occurrence of new organ failure in critically ill patients, independently of respiratory status and severity of critical illness. The causality link could be addressed in an interventional trial.
- 30 July 2020
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 48 (10) , 1471-1479
Association Between Anxiety and New Organ Failure, Independently of Critical Illness Severity and Respiratory Status: A Prospective Multicentric Cohort Study
Objectives: Anxiety results from the anticipation of a threat and might be associated with poor outcome in the critically ill. This study aims at showing that anxiety at admission in critically ill patients is associated with new organ failure over the first 7 days of ICU hospitalization independently of baseline organ failure at admission. Design: Prospective multicenter cohort study. Setting: Three mixed ICU from April 2014 to December 2017. Patients: Coma-, delirium-, and invasive mechanical ventilation-free patients admitted to the ICU were included. Interventions: None. Measurements and Main Results: “State anxiety” was assessed using the state component of the State-Trait Anxiety Inventory State. Severity of illness was measured using Simplified Acute Physiology Score II and Sequential Organ Failure Assessment scores. Primary endpoint was a composite of occurrence of death or new organ failure in the first 7 days after admission. Three hundred ninety-one patients were included; 159 of 391 women (40.7%); median age 63 years (49–74 yr); median Simplified Acute Physiology Score II 28 (19–37). Two hundred three out of 391 patients (51.9%) reported moderate to severe anxiety (State-Trait Anxiety Inventory State ≥ 40). One hundred two out of 391 patients (26.1%) developed a new organ failure. After adjustment to Simplified Acute Physiology Score II and Sequential Organ Failure Assessment, State-Trait Anxiety Inventory State greater than or equal to 40 was associated with the primary endpoint (odds ratio, 1.94; 95% CI, 1.18–3.18; p = 0.009) and respiratory failure. In post hoc analysis, State-Trait Anxiety Inventory State greater than or equal to 40 was associated with new organ failure independently and notably of respiratory status at admission (dyspnea-Visual Analogic Scale and Paco 2 ≥ 45 mm Hg). Conclusions: Moderate to severe anxiety at ICU admission is associated with early occurrence of new organ failure in critically ill patients, independently of respiratory status and severity of critical illness. The causality link could be addressed in an interventional trial.
- 1 February 2016
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 33 (2) , 190-191
Erratum de l’article : « La pneumocystose chez le patient adulte non infecté par le VIH » [Rev. Mal. Respir. 2015;32:985–990]
- 1 February 2016
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 33 (2) , 190-191
Erratum de l’article : « La pneumocystose chez le patient adulte non infecté par le VIH » [Rev. Mal. Respir. 2015;32:985–990]
- 15 April 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (8_Suppleme) , 630
Abstract 630: ERCC1-202 isoform is responsible for all known functions of ERCC1.
- 15 April 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (8_Suppleme) , 630
Abstract 630: ERCC1-202 isoform is responsible for all known functions of ERCC1.
- 1 January 2007
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 24, 24
39 Place de la chirurgie dans la prise en charge des hémoptysies graves admises en réanimation
- 1 January 2007
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 24, 24
39 Place de la chirurgie dans la prise en charge des hémoptysies graves admises en réanimation